SynovAI

Retrosynthesis Realized

Intellectual Property

Exclusive Global Yale License

Expanding Patent Portfolio

Strategic Affiliations

Boehringer Ingelheim

Pfizer

NVIDIA

GRACE

standard

moderna

Peer Reviewed Science


nature communications

Site-specific template generative approach for retrosynthetic planning

JCTC

Holographic Gaussian Boson Sampling with Matrix Product States on 3D cQED Processors

The SynovAI team delivers leading innovation, technical expertise, and operational experience

Victor Batista, PhD
Co-Founder
Board Member
Kirkwood Professor of Chemistry

Jessica Freeze, PhD
Co-Founder
Board Member
President & Chief Executive Officer

Klas Holmlund, MBA, CFA
Co-Founder
Chief Operating Officer

Corey Jones, PhD
Co-Founder
Chief Scientific Officer

Costly tradeoffs from growing molecular complexity magnifies launch risks and increases production costs

Analgesics (Pain)

ibuprofen

1998: 3 steps



atogepant

2021: 10 steps



Anti-virals (HIV)

zidovudine

1987: 3 steps



lenacapavir

2022: 20+ steps





SynovAI's generative retrosynthesis platform demonstrates real synthetic improvement across key metrics

Orforglipron – Oral GLP-1 Inhibitor currently in Phase III trials

Current Synthesis





11 steps



~$4.1/g



10 steps



~$11.0/g

SynovAI Synthesis Improvements

- Planning Time
- Synthesis Duration
- Purification
- Yield
- Waste/Greenness
- COGS



Estimated cost reduction of ~30-45%



7 steps



~$1.3/g



6 steps



~$0.9/g

SynovAI's platform outperforms other computational methods with a clear technological competitive edge

KRAS G12C Inhibitor Intermediate – Tumorigenic Mutation: *Demonstrated novel synthetic pathway, unseen by current commercial software, within two weeks*

SynovAI[1]



Previous Best[2]



	Competition	SynovAI
No Data Querying	—	✓
No Hand-Coded Rules	—	✓
Novel Pathways	—	✓
Experimentally Validated	✓	✓
Efficient Scaling with Pathway Size	—	✓
Prototype Ready for Use	✓	✓

1) https://doi.org/10.26434/chemrxiv-2024-zscw8
2) https://doi.org/10.1021/acs.oprd.3c00363

SynovAI's technology is ready for deployment and growth potential is substantial



~35k

Identified targets

Platform Live

~13.1k

Compounds evaluated

Process Validation

IP generation

Process based platform development enables creation of new IP and potential for multiple strategic partnerships

Source: EPA

SynovAI's chemical retrosynthesis solution can provide exclusive and significant value across many industries globally



COFCO · KERRY · BUNGE · dsm-firmenich · Cargill · Givaudan · ADM · Ingredion · BAYER · DOW · EVONIK · ARKEMA · 3M · LyondellBasell · syngenta · DUPONT · CLARIANT · Formosa Plastics · sabic · BASF

MERCK · GSK · NOVARTIS · GILEAD · novo nordisk · AMGEN · Pfizer · VERTEX · GRACE · Biogen · Johnson&Johnson · Boehringer Ingelheim · COLGATE-PALMOLIVE · P&G · Kimberly-Clark · Mondelēz International · Reckitt Benckiser · General Mills · Coca-Cola · Unilever · SCJohnson

Source: ACC 2023 Guide to the Business of Chemistry; assumes aggregate cross-industry Cost-of-Goods-Sold (COGS) and retrosynthesis applicability of 30% and 5%, respectively

SynovAI's business model delivers immediate partnerships benefits, IP generation capabilities and enduring revenue scalability

Today	Short Term	Long Term
Industry Platform Partnerships	→ Diversified CDMO Partnerships	→ Improved Process Patents
State-of-the-Art Platform	→ Synthetic Pathway Validation	→ Commercial Volumes
Customer Guided Design	→ Customer Confidence	→ Market Leadership
Early and Ongoing Revenue/Cash Flow	Multiplicative Growth	Business Sustainability

Projected Timeline: SynovAI can deliver multiple valuation inflection points in rapid succession



Potential valuation and fundraising catalyst

Come talk to us!

Jessica

Freeze

Klas

Holmlund

Victor

Batista

Corey

Jones

info@synovai.net